OpenAI Eyes IPO Filing as Early as This Week Amid Rising AI Competition 
Trump-China Summit Yields Limited Progress on Trade and Tech Cooperation 
Trump to Swear In Kevin Warsh as New Federal Reserve Chair Amid Inflation Concerns 
Japan Posts Strong April Trade Surplus as Exports Surge Amid Robust U.S. and China Demand 
Wall Street Rebounds as U.S.-Iran Peace Deal Hopes Lift Markets and Ease Oil Prices 
Cuba needs a long-term solution to its energy crisis 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
H.B. Fuller Eyes Advanced Medical Solutions in Potential £600M Takeover Deal 
SpaceX Starship V3 Test Flight Boosts IPO Momentum Ahead of Historic Market Debut 
Dollar Slips as Risk Appetite Grows Amid Nvidia Rally and Iran Peace Hopes 
Texas Sues Meta Over WhatsApp Encryption Claims 
OpenAI Expands Globally with First Overseas AI Lab in Singapore 
Oil Prices Rebound as U.S.-Iran Talks Continue to Influence Global Crude Market 
Goldman Sachs Sees Stronger U.S. Dollar as Global Economic Gaps Widen 
Anthropic Revenue Surge Signals Strong AI Market Momentum in 2026 
China Delays Pentagon Official’s Beijing Visit Amid Taiwan Arms Deal Tensions 
X Corp Loses Legal Battle Over Australia Child Safety Fine 
Celltrion revealed on Thursday, Sept. 23, that it would be supplying its rapid COVID-19 test kit called DiaTrust to the US government. This happened after the nation’s Department of Defense awarded the contract to them.
The South Korean biopharma stated that starting October 1st, its American division, Celltrion USA, will begin delivering the DiaTrust rapid test kits to 25,000 locations. The sites include nursing homes, coronavirus testing centers, and military facilities.
According to The Korea Herald, based on the agreement signed by Celltrion and the US Defense Logistics Agency, the United States could purchase additional kits if necessary. For the initial supply, the amount of the contract is said to be $626.61 million or 738.2 billion in Korean won.
Details for the initial order, like how many would be delivered was not disclosed. However, the publication stated that Bloomberg mentioned that the deal was for a total of 19 million DiaTrust test kits. With its contract with the DOD, Celltrion became the US’ largest supplier of rapid COVID-19 test kits.
“The fact that we were awarded a procurement contract by the DLA after having passed its strict screen process is a recognition of Celltrion’s technology and supply capability,” Celltrion USA chief executive officer, Bonjoong Kim, said in a press release. “With the COVID-19 pandemic still not showing signs of waning, we plan to focus on executing this contract as diligently as possible and further solidify the external credibility of Celltrion’s diagnostic test kits portfolio.”
It was added that the DiaTrust kits that will be delivered through this deal are point-of-care tests (POCT). This means that the COVID-19 rapid test will only be used in the presence of medical professionals. Apparently, this is for safety and to ensure that the process is done properly for more accurate results.
As per Pulse News, DiaTrust was jointly developed by Celltrion and Humasis, a Korean R&D company. The test kit was authorized by the US Food and Drug Administration (FDA) for emergency use last April.
Finally, Celltrion’s DiaTrust rapid COVID-19 kit is an antigen test that is used in medical settings. It can reveal the results on the spot since it only takes as little as 15 minutes to complete.
